In the past decade, increasing evidence has demonstrated that lipid droplet-associated proteins may represent potential therapeutic targets for the treatment of NAFLD/NASH given the critical role they play in regulating the biogenesis and metabolism of lipid droplets. The gene discussed is PLIN1; the disease is metabolic dysfunction-associated steatohepatitis.